MedTrace Logo

Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL

NCT04662528 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2021-09-16

No results posted yet for this study

Summary

To determine the efficacy of MAT9001 compared to placebo in lowering fasting triglyceride levels in subjects with very high fasting triglyceride levels ≥ 500 and \< 2000 mg/dL.

Conditions

Interventions

DRUG

Placebo

4 x 1g capsules/day

DRUG

MAT9001 (omega-3 pentaenoic acid)

4 x 1g capsules/day

Sponsors & Collaborators

  • Covance

    collaborator INDUSTRY

  • Matinas Biopharma, Inc

    lead INDUSTRY

Principal Investigators

  • Judith Johnson · Matinas BioPharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2022-08-31
Completion
2022-10-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04662528 on ClinicalTrials.gov